Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies)

D. Fialová, B. Laffon, V. Marinković, L. Tasić, P. Doro, G. Sόos, J. Mota, S. Dogan, J. Brkić, JP. Teixeira, V. Valdiglesias, S. Costa, EUROAGEISM H2020 project and WG1b group “Healthy clinical strategies for healthy aging” of the EU COST Action IS 1402,

. 2019 ; 75 (4) : 451-466. [pub] 20190104

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034842

Grantová podpora
EU COST Action IS1402 "Ageism - a multi-national, interdisciplinary perspective" (2015-2018) European Cooperation in Science and Technology
EUROAGEISM Horizon 2020 project EC no. 764632 MSCA-ITN (2017-2021) H2020 Marie Skłodowska-Curie Actions

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost) od 2008-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 30610276
DOI 10.1007/s00228-018-2603-5
Knihovny.cz E-zdroje

INTRODUCTION: The importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the "age-blind" approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches. METHODOLOGY: A narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise). RESULTS: Older patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of some nonpharmacological  strategies is highly underestimated in older adults in contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinical studies. CONCLUSION: Several regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034842
003      
CZ-PrNML
005      
20191011110415.0
007      
ta
008      
191007s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00228-018-2603-5 $2 doi
035    __
$a (PubMed)30610276
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Fialová, Daniela $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic. daniela.fialova@faf.cuni.cz. Department of Geriatrics and Gerontology, 1st Faculty of Medicine in Prague, Charles University, Prague, Czech Republic. daniela.fialova@faf.cuni.cz.
245    10
$a Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies) / $c D. Fialová, B. Laffon, V. Marinković, L. Tasić, P. Doro, G. Sόos, J. Mota, S. Dogan, J. Brkić, JP. Teixeira, V. Valdiglesias, S. Costa, EUROAGEISM H2020 project and WG1b group “Healthy clinical strategies for healthy aging” of the EU COST Action IS 1402,
520    9_
$a INTRODUCTION: The importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the "age-blind" approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches. METHODOLOGY: A narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise). RESULTS: Older patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of some nonpharmacological  strategies is highly underestimated in older adults in contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinical studies. CONCLUSION: Several regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a lékové předpisy $x normy $x statistika a číselné údaje $7 D011307
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geriatrické hodnocení $7 D015577
650    _2
$a lidé $7 D006801
650    _2
$a nevhodné předepisování $x statistika a číselné údaje $7 D057970
650    _2
$a mužské pohlaví $7 D008297
650    12
$a polypharmacy $7 D019338
650    _2
$a seznam potenciálně nevhodných léčiv $x statistika a číselné údaje $7 D000067561
650    _2
$a prevalence $7 D015995
650    _2
$a randomizované kontrolované studie jako téma $x statistika a číselné údaje $7 D016032
650    _2
$a rizikové faktory $7 D012307
651    _2
$a Evropa $7 D005060
651    _2
$a Turecko $7 D014421
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Laffon, Blanca $u DICOMOSA Group, Department of Psychology, Area of Psychobiology, Universidade da Coruña, A Coruña, Spain.
700    1_
$a Marinković, Valentina $u Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
700    1_
$a Tasić, Ljiljana $u Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
700    1_
$a Doro, Peter $u Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
700    1_
$a Sόos, Gyӧngyver $u Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
700    1_
$a Mota, Jorge $u Centro de Investigação em Actividade Fìsica, Saúde e Lazer (CIAFEL), University of Porto, Porto, Portugal.
700    1_
$a Dogan, Soner $u Department of Medical Biology, School of Medicine, Yeditepe University, Istanbul, Turkey.
700    1_
$a Brkić, Jovana $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic.
700    1_
$a Teixeira, João Paulo $u Department of Environmental Health, Portuguese National Institute of Health, Porto, Portugal. EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal.
700    1_
$a Valdiglesias, Vanessa $u DICOMOSA Group, Department of Psychology, Area of Psychobiology, Universidade da Coruña, A Coruña, Spain.
700    1_
$a Costa, Solange $u Department of Environmental Health, Portuguese National Institute of Health, Porto, Portugal. EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal.
710    2_
$a EUROAGEISM H2020 project and WG1b group “Healthy clinical strategies for healthy aging” of the EU COST Action IS 1402
773    0_
$w MED00001613 $t European journal of clinical pharmacology $x 1432-1041 $g Roč. 75, č. 4 (2019), s. 451-466
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30610276 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011110835 $b ABA008
999    __
$a ok $b bmc $g 1451502 $s 1073392
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 75 $c 4 $d 451-466 $e 20190104 $i 1432-1041 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol $x MED00001613
GRA    __
$a EU COST Action IS1402 "Ageism - a multi-national, interdisciplinary perspective" (2015-2018) $p European Cooperation in Science and Technology
GRA    __
$a EUROAGEISM Horizon 2020 project EC no. 764632 MSCA-ITN (2017-2021) $p H2020 Marie Skłodowska-Curie Actions
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace